* Ansan Inc., of South San Francisco, signed a licensing agreementwith Boehringer Ingelheim, of Ingelheim, Germany, to acquire rightsin the U.S. and Europe to develop an intravenous formulation of thedrug apafant for all indications. The drug, an agonist of plateletactivating factor, initially will be developed for acute pancreatitis.
* Aronex Pharmaceuticals Inc., of The Woodlands, Texas, saidunderwriters for its recent public offering exercised overallotmentoptions on 900,000 shares at $5 each. Aronex expects to net $32.1million from the sale of 6.9 million shares.
* Bio-Technology General Corp., of Iselin, N.J., said its humangrowth hormone has been launched in Italy under the trademarkZomacton, for treatment of growth hormone deficiency in children.The product will be sold by the Dutch-based Ferring Group, whichalready markets the product for Bio-Technology General throughoutEurope.
* Genzyme Transgenics Corp., of Framingham, Mass., reachedagreement with Boehringer Mannheim GmbH, of Mannheim,Germany, to conduct a study of the expression of a monoclonalantibody in the milk of transgenic mice, in exchange for milestonepayments.
* Hemosol Inc., of Toronto, completed a previously announcedprivate placement of 2.5 million warrants for gross proceeds ofC$13.25 million. Each warrant can be exercised for one commonshare. The company is developing blood-related proteins.
* Micrologix Biotech Inc., of Vancouver, British Columbia, saidsome of its antibiotics from the MBI 10 series of geneticallyengineered peptides were effective in animals in treating lethalbacterial infections.
* NaPro Biotherapeutics Inc., of Boulder, Colo., registered for afollow-on offering of 2 million primary shares of stock. The companymanufactures the anti-cancer compound paclitaxel. Underwriters areVector Securities International Inc., of Deerfield, Ill., and J.P.Morgan & Co., of New York.
* SunPharm Corp., of Jacksonville, Fla., signed an agreement withthe Mayo Clinic in Jacksonville, whose researchers will testSunPharm's polyamine analogues in animal models of Alzheimer'sdisease progression.
* Synsorb Biotech Inc., of Calgary, Alberta, began a Phase IIIdouble-blind, placebo-controlled study of Synsorb Pk, which is beingdeveloped for hemolytic uremic syndrome, or hamburger disease,which primarily is caused by E. coli bacteria. The study will enroll300 patients ages 6 months to 15 years old.
* Theratech Inc., of Salt Lake City, said its board approved a 3-for-2stock split. One additional share will be distributed on June 28, 1996,for each two shares held by stockholders on June 14, 1996.
* Vyrex Corp., of La Jolla, Calif., said PolluFil Trading S.A., aholding company in Geneva, Switzerland, will proceed withcommercialization of Vyrex's Vantox technology for use in makingan antioxidant cigarette filter. It represents another potential use forVyrex's antioxidant technology outside the original focus ofrespiratory diseases and disorders.
(c) 1997 American Health Consultants. All rights reserved.